Linezolid is an oxazolidinone antibiotic recommended for XDR-TB, particularly for cases resistant to multiple first-line drugs.
It inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing infection spread.
Other drugs listed have different antibacterial spectrums, with limited efficacy against XDR-TB.